

PRECISION ONCOLOGY ALLIANCE


¹Division of Gynecologic Oncology, RUSH University Medical Center, Chicago, IL; ²Caris Life Sciences, Phoenix, AZ; ³Division of Gynecologic Oncology, Washington University, St. Louis, MO; ⁴University of Cincinnati Cancer Center; Cincinnati, OH; ⁵Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN; ⁶Division of Gynecologic Oncology, University of Alabama, Birmingham, AL

Objective

We aimed to describe the genomic and clinical characteristics of the no specific molecular profile (NSMP: POLE-WT, MSS, and TP53-WT) endometrial cancer (EC) tumor cohort and to clarify the utility of estrogen receptor (ER) status.

Methods

- 4162 NSMP EC tumors were analyzed by NGS (NextSeq, 592 genes or NovaSeq, WES) (Caris Life Sciences, Phoenix, AZ).
- Survival data were obtained from insurance claims data and calculated from first treatment to last contact for molecularly defined cohorts.
- Survival and mutation enrichment were compared among several IHC thresholds (regardless of staining intensity): •<1% or <10% (ER-neg) • 1-49% or 10-49% (ER-low) •>50% (ER-H)
- Hazard ratios (HR) were calculated by Cox proportional hazards, with pvalues determined by logrank tests. Statistical significance was assessed using chi-square analysis.





Genomic and immunohistochemical characterization of NSMP endometrial cancer: a novel approach to estrogen receptor positivity

Alexander C. Cohen¹, Sharon Wu², Ninad Kulkarni², Matthew J. Oberley², Premal H. Thaker³, Thomas J. Herzog⁴, Matthew A. Powell³, Britt K. Erickson⁵, Michael D. Toboni⁶







Results

eature Type (Click to high

Gene Copy Number - Cl

Amplification Frequency - NGS 592 and

Transcriptomic signatures - Biomarkers

Fusion Variant

ature Type (Click to highligh

Amplification Frequency - NGS 592 and V

eature Type (Click to highlight) Amplification Frequency - NGS 592 and V Median IHC Intens Median IHC Perce

Conclusions

other cohorts.

SGO

ANNUAL MEETING

ON WOMEN'S CANCER

SEATTLE, WA · 2025

Among tumors with longer post-carbo

survival, KRAS-MT were enriched in

19.4%, *p*=0.047) tumors but not in

the ER-neg (42.9% vs 22.9%,

p<0.001) and ER-low (36.4% vs

ER-high tumors (12% vs 17.8%,

Progesterone receptor (PR)+ IHC

ARID1A-MT (83.3% vs 55.2%, p=0.01)

were enriched among ER-low tumors

CTNNB1-MT were enriched in ER-H

tumors (62% vs 43.7%, p=0.02) with

longer post-carbo survival but not in

(79.6% vs 50.8%, p=0.002) and

with longer post-carbo survival.

p=0.316).

- NSMP tumors with ER>50% have good prognoses.
- ER<10% and ER 10-49% tumors have similar prognoses. But NSMP ER<1% tumors have worse survival than ER 1-49%.
- Mutation enrichment analysis of our ER-low cohort was distinct from ERneg
- These observations remain even after excluding clear cell tumors.
- 27% of our ER 1-49% cohort would be classified as "ER negative" using a <10% threshold.
- Using a <1% and 1-49% thresholds (ER-neg and ER low) should be considered.

